Skip to main content
MAXCYTE, INC. logo

MAXCYTE, INC. — Investor Relations & Filings

Ticker · MXCT ISIN · US57777K1060 LEI · 54930053YHXULRFCU991 US Professional, scientific and technical activities
Open in API
Filings indexed 767 across all filing types
Latest filing 2024-08-07 Earnings Release
Country US United States of America
Listing US MXCT

About MAXCYTE, INC.

https://www.maxcyte.com/

MaxCyte, Inc. is a cell-engineering company that provides enabling platform technologies to advance the discovery, development, and commercialization of cell-based therapeutics. Its core offering is the ExPERT™ platform, which utilizes proprietary Flow Electroporation® technology for efficient, scalable, and non-viral transfection of complex cells. This technology supports a wide range of applications, including cell therapy, gene editing, antibody and protein production, and vaccine development. Additionally, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate the safety of gene-edited products by detecting on- and off-target effects. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.

Recent filings

Filing Released Lang Actions
Second Quarter and Half-Year Results
Earnings Release Classification · 1% confidence The document is a press release from MaxCyte, Inc. announcing its financial results for the second quarter and half-year ended June 30, 2024. It includes key financial highlights, revenue breakdowns, and updated guidance. It is not a full 10-K or an interim report, but rather the initial announcement of these results, which fits the definition of an Earnings Release (ER). Q2 2024
2024-08-07 English
10-Q
Interim / Quarterly Report Q2 2024
2024-08-06 English
8-K
Regulatory Filings
2024-08-06 English
Director's Dealing 2024
Director's Dealing
2024-08-05 English
Total Voting Rights
Regulatory Filings Classification · 1% confidence The document is an official announcement from MaxCyte, Inc. regarding the issuance of new common stock due to the exercise of share options and the vesting of restricted stock units. It explicitly provides the updated total number of issued shares and total voting rights, which shareholders must use as a denominator for regulatory notifications. This falls under the category of share capital changes and voting rights updates, which is best classified as 'Share Issue/Capital Change' (SHA).
2024-08-01 English
Exercise of options and PDMR dealing
Director's Dealing Classification · 1% confidence The document is an official notification regarding a transaction in company shares by a Non-Executive Director (John Johnston). It explicitly uses the header 'NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES' (PDMR), which is the standard regulatory format for reporting insider dealings. This falls directly under the 'Director's Dealing' category.
2024-07-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.